A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC who are BCG Naïve/Received Incomplete BCG Treatment
- Investigator
- Kethandapatti Balaji
- Status
- Accepting Candidates
- Ages
- 18 Years - 100 Years
- Sexes
- All
BCG in combination with durvalumab in adult BCG-naive, high-risk NMIBC participants
- Investigator
- Kethandapatti Balaji
- Status
- Accepting Candidates
- Ages
- 18 Years - 99 Years
- Sexes
- All
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
- Investigator
- Kethandapatti Balaji
- Status
- Accepting Candidates
- Ages
- 18 Years - 100 Years
- Sexes
- All
